Bristol-Myers Squibb Co. (NYSE:BMY)

sellhigh98 (< 20) Submitted: 8/20/2012 2:34:25 PM : Start Price: $30.65 BMY Score: +38.31

BMY recently had a dip in share price because one of it' drugs did not receive FA approval. Shares dropped 6+% the day it was announced. I had recently bought at 33 and change and happily added to my position when this slide occurred. I would recommend buying at anytime during this consolidation period. It is my belief that Bristol will outperform in the mid/long term due to it's juicy and sustainable dividend, it's smaller market cap. when compared to companies like Merck or Pfizer, it's wonderful return on equity and operating margins which show it has strong profitability and management. Also, its cash of 5.03B could just about pay off it's debt(5.42B) if needed. Shares outstanding aren't too diluted (unlike companies such as Ford-F NYSE). Bristol also has a strong current ratio of 1.63. Shares are also trading below their 50 and 200 day moving averages, making entering a new position even more promising. Finally, BMY has a current assets: liabilities ratio of 15.318B: 7.780B and total A:L of 32.97:17.014B. This gives BMY a good short and long term outlook. The only thing to weary of is that it has an average 1y target estimate of 34.63, however the "professional's thoughts have never really carried an weight in my mind before".

To good investing from good people